Safety and Tolerability Evaluation of QRL-201 in Patients with Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study

The primary objective of this study is to evaluate the **safety** and **tolerability** of QRL-201 in patients with **amyotrophic lateral sclerosis** (ALS). This is clinically relevant as ALS is a progressive neurodegenerative disease with limited treatment options, and understanding the safety profile of new therapeutic agents is crucial for developing effective interventions. The study is designed as a multi-center, randomized, double-blind, placebo-controlled multiple ascending dose trial, which is a robust approach to assess the potential risks and benefits of QRL-201 in this patient population.

The clinical trial involves a total of **57 participants** diagnosed with **Amyotrophic lateral sclerosis**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, nor are there any particular lifestyle considerations such as diet or physical activity mentioned. The selection criteria for the trial population have not been detailed by the sponsor.

The clinical trial is designed as a **randomized**, **double-blind**, **placebo-controlled** study to assess the safety and tolerability of QRL-201 in patients with **amyotrophic lateral sclerosis**. This Phase 1 trial will involve multiple ascending doses to evaluate the investigational product's effects. The trial is expected to commence recruitment on June 1, 2023, and is projected to conclude by October 1, 2025. Participants will be involved in the study for the duration of the trial, with specific timelines for individual involvement determined by the dosing schedule and follow-up requirements.

The sequence of study visits begins with an inclusion visit, where potential participants will undergo screening to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational product or a placebo. The study will include several follow-up visits to monitor safety, tolerability, and any adverse events. These visits will be conducted at regular intervals as per the study protocol. The end-of-study visit will mark the completion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the investigational product's safety profile.

Participants may be subject to early termination from the study if they experience significant adverse events, fail to comply with the study protocol, or withdraw consent. The trial's design ensures that all procedures are conducted under strict regulatory and ethical guidelines to safeguard participant well-being and data integrity. The study's findings will contribute to the understanding of QRL-201's safety and tolerability in the target population, potentially informing future research and therapeutic strategies for **amyotrophic lateral sclerosis**.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it is classified as an orphan drug. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available in the provided data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is June 1, 2023, with an anticipated end date of October 1, 2025. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically involve initial assessments of pharmacokinetics and pharmacodynamics, which may include measuring biomarker levels or other relevant physiological responses. The trial will likely employ standardized methods and validated instruments to ensure the accuracy and reliability of data collection and analysis. The schedule for efficacy assessments is not specified, but such trials often include multiple timepoints to monitor changes over the treatment period. The absence of detailed endpoints suggests a focus on exploratory outcomes to inform subsequent trial phases.